Patents Assigned to Rugen Holdings (Cayman) Limited
  • Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
    Patent number: 11752155
    Abstract: Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: September 12, 2023
    Assignee: Rugen Holdings (Cayman) Limited
    Inventors: Gideon Shapiro, Dorothy G. Flood
  • 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
    Patent number: 11136328
    Abstract: Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: October 5, 2021
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
    Patent number: 11000526
    Abstract: Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 11, 2021
    Assignee: Rugen Holdings (Cayman) Limited
    Inventors: Gideon Shapiro, Dorothy G. Flood
  • 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
    Patent number: 10584127
    Abstract: Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 10, 2020
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
    Patent number: 10420768
    Abstract: Disclosed are chemical entities of formula I: wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula I, and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: September 24, 2019
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
    Patent number: 10294230
    Abstract: Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 21, 2019
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
    Patent number: 10221182
    Abstract: Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R1, R3, R4 and R5 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: March 5, 2019
    Assignee: RUGEN HOLDINGS (CAYMAN) LIMITED
    Inventor: Gideon Shapiro
  • Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
    Patent number: 10030026
    Abstract: Disclosed are chemical entities of formula (I) wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: July 24, 2018
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
    Patent number: 9968610
    Abstract: Disclosed are chemical entities of formula I: wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula I, and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: May 15, 2018
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
    Patent number: 9567341
    Abstract: Disclosed are chemical entities of formula I: wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula I, and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 14, 2017
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro